Press Releases

Date Title and Summary Additional Formats
Toggle Summary Evoke Pharma Signs Commercial and Financial Agreement for its Lead Product Gimoti™ in the U.S. with Novos Growth Partners
Novos to provide fully integrated commercial function for Evoke and non-dilutive financing for the commercialization of Gimoti, extending cash runway into 2020 Evoke will retain greater than 80% of product profits following approval SOLANA BEACH, Calif. , Jan.
View HTML
Toggle Summary Evoke Pharma Reports Third Quarter 2018 Results
April 1, 2019 PDUFA date for Gimoti™ NDA Cash runway extended through June 2019 SOLANA BEACH, Calif. , Nov. 13, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial
View HTML
Toggle Summary Evoke Pharma’s Gimoti™ NDA Accepted for FDA Review
April 1, 2019 PDUFA Target Goal Date Gimoti Brand Name Conditionally Accepted SOLANA BEACH, Calif. , Aug. 16, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company’s
View HTML
Toggle Summary Evoke Pharma Reports Second Quarter 2018 Results and Recent Highlights
Gimoti ™ NDA submitted to FDA on June 1 st ; awaiting 74-Day FDA filing communication letter Gender-specific patents granted for Gimoti in the European Union and Mexico SOLANA BEACH, Calif. , Aug. 09, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company
View HTML
Toggle Summary Evoke Announces FDA Submission of New Drug Application for Gimoti™
Company to host a corporate update conference call today, June 4, 2018 at 4:30pm EST SOLANA BEACH, Calif. , June 04, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the submission
View HTML
Toggle Summary Evoke Pharma Reports First Quarter 2018 Results and Highlights
The Company will hold a conference call following submission of Gimoti NDA NDA submission for Gimoti™ on track for second quarter of 2018 Announced discovery of sex-based pharmacokinetic differences for Gimoti Waiver of the PDUFA fee for Gimoti NDA granted by FDA Cash runway extended into April
View HTML
Toggle Summary Evoke Granted Gender Specific Patent for Gimoti™ in Mexico
First North American patent for Gimoti with expiry in 2032 SOLANA BEACH, Calif. , May 10, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Mexican Institute of Industrial
View HTML
Toggle Summary Evoke Granted First Gender Specific Patent for Gimoti™
European Union patent applies to 38 member states with expiry extended to 2032 SOLANA BEACH, Calif. , April 30, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) d­­iseases, today announced that the European
View HTML
Toggle Summary Evoke Announces Agreement with Mallinckrodt to Amend Milestone Payments
Cash runway extended to January 2019 SOLANA BEACH, Calif. , March 26, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) d­­iseases, today announced that it has amended the Company’s agreement with
View HTML
Toggle Summary Evoke Pharma Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Highlights
Successfully completed pivotal pharmacokinetic trial and finalized the proposed to-be-marketed Gimoti™ dose Announced discovery of sex-based pharmacokinetic differences for Gimoti™ Met with FDA regarding NDA women-only filing strategy and post-marketing plans 505(b)(2) NDA submission planned for
View HTML